How successful is blinatumomab?
Those treated with blinatumomab also did substantially better on a measure known as event-free survival: 69% versus 43%. An event was defined as a relapse of their cancer, death, diagnosis of a second cancer, or failure to achieve complete remission. Overall survival also favored the blinatumomab group.
How do you read MRD results?
An MRD positive test result means that residual (remaining) disease was detected. A negative result means that residual disease was not detected. After treating cancer, any remaining cancer cells in the body can become active and start to multiply, causing a relapse of the disease.
Does MRD mean remission?
A positive MRD test means that cancer cells were found. This does not necessarily mean you’re no longer in remission, but it does mean there is a risk of the cancer returning. This result also might indicate that you and the doctor may need to discuss new treatment options.
Is blinatumomab a monoclonal antibody?
Blinatumomab is a special kind of monoclonal antibody because it can attach to 2 different proteins at the same time. One part of blinatumomab attaches to the CD19 protein, which is found on B cells, including some leukemia and lymphoma cells.
Is blinatumomab an antibody?
Blinatumomab is the first-in-class BiTE antibody approved for treatment of refractory ALL [46, 47, 58–64]. Blinatumomab was first reported in a clinical phase I trial in 38 patients with refractory non-Hodgkin lymphoma [58].
What is a positive MRD?
y Minimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
How long can you be in remission?
In a complete remission, all signs and symptoms of cancer have disappeared. If you remain in complete remission for 5 years or more, some doctors may say that you are cured. Still, some cancer cells can remain in your body for many years after treatment. These cells may cause the cancer to come back one day.
What is considered MRD positive?
When a patient tests positive for MRD, it means that there are still residual cancer cells in the body after treatment. When MRD is detected, this is known as “MRD positivity.” When a patient tests negative, no residual cancer cells were found.
What kind of drug is blinatumomab?
Blinatumomab is in a class of medications called bispecific T-cell engager antibodies. It works by slowing or stopping the growth of cancer cells in your body.
How is blinatumomab produced?
Because of its single-chain structure, blinatumomab can be produced with a stable purified monomeric formulation in large quantities for clinical use [23, 24, 28, 41]. Blinatumomab has been shown to increase inflammatory cytokine production, specifically IL-2, IFN-γ, TNF-α, IL-4, IL-6, and IL-10 [53].
Does blinatumomab have a role in B cell non-Hodgkin’s lymphoma?
Introduction: Blinatumomab, a first-in-class bispecific T cell engager, is a member of a novel class of bispecific antibody constructs with dual binding specificities. While its primary clinical use has been in B cell acute lymphoblastic leukemia, its role in the treatment of B cell non-Hodgkin’s Lymphoma (NHL) is less well established.
What type of drug is blinatumomab?
Blinatumomab belongs to an emerging class of anti-cancer therapeutics referred to as bispecific T-cell engaging antibodies. The Food and Drug Administration approved its use in relapsed or refractory adult Philadelphia chromosome-negative B-cell precursor ALL in December of 2014.
Does blinatumomab cause tumor lysis syndrome?
Tumor lysis syndrome Tumor lysis syndrome has been observed in patients receiving blinatumomab. Appropriate prophylactic measures, including adequate hydration and pretreatment cytoreduction, should be considered in patients receiving treatment, especially those with high leukemic burden.
What are the limitations of blinatumomab in the treatment of all?
Blinatumomab represents a significant addition to the treatment options for ALL, but it is not without its limitations, of which are its short-half life, necessitating long-term CIVI, and the eventual emergence of CD19-negative clones. Continual development of the agent involves assessing its role i …